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ABSTRACT 
Despite impressive advances in drug discovery methods, predicting cellular response to anticancer drugs remains 
challenging. In glioblastoma multiforme, this fact is even marked as many promising drugs were followed by 
disappointment. As a result, the aim of this study is to clarify the effects of inhibition of 3-phosphoinositide-dependent 
protein kinase-1 (PDK1) in glioblastoma multiforme, while exploring how the focus on potency might ignore the 
potential impact of variation in other pharmacological parameters. The evaluation of the induced drug perturbation 
in glioblastoma cancer cells and a multiparametric characterization dose-response of two PDK1 inhibitors were 
performed. Singular analysis of potency would lead to the conclusion that FC100 compound would be the most 
promising to treat glioblastoma multiforme. However, exploring other pharmacological parameters shows the opposite 
giving more information about the cell response. The study shows that potency should not be the critical factor in 
developing new drugs as our most potent compound lacks growth inhibition effect. So, the evaluation of promising 
drugs during the drug discovery phase needs to be re-evaluated and multiparametric dose-response analysis might be a 
useful approach to compare drugs and potentially better characterization of both drug and disease profiles.
INTRODUCTION
Nowadays and regarding the actual world economic 
conjuncture on the science community, the inefficiencies of the 
drug discovery and development process are a forthcoming subject 
(Antman et al., 2012). Despite critical discoveries in science and 
technology, expressions such as “Valley of Death” keeps appearing 
to describe these inefficiencies, and so there is an urge for a shift 
on the business and scientific background of drug research & 
development (R&D) (Abou-Gharbia and Childers, 2014).
In oncology, the R&D seems to be even more complex 
as the success rate of drug candidates is abysmally lower when 
compared with the other areas of healthcare (Bhattacharjee, 2012; 
Williams, 2015). Besides this “curse” in R&D, developing new 
drugs against a cancer such as glioblastoma multiforme (GBM) 
is particularly challenging due to a variety of reasons related 
with both compound and tumor characteristics, resulting in 
unsuccessful approaches and drugs, culminating in a fatal outcome 
(Olar and Aldape, 2014). GBM is classified by the World Health 
Organization as a grade VI malignant astrocytoma (Schonberg et 
al., 2013), being the most common intrinsic primary brain tumor in 
adults, and represents over 80% of diffuse gliomas (Toda, 2013). 
In the case of this type of tumor, among other facts, their origin, 
structure, biology, cellular metabolism, and microenvironment are 
still unclear (Behnan et al., 2013; Lima et al., 2012).
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One of the proteins, which is involved in many processes 
related to GBM, is the 3-phosphoinositide-dependent protein 
kinase-1 (PDK1). It acts as a master upstream protein kinase, 
phosphorylating and activating a subgroup of the AGC (protein 
kinase A, protein kinase G, protein kinase C) kinase family (which 
it is part of) implicated in the control of cell growth, proliferation, 
survival, and metabolism regulation (Nesi, 2011; Sephton et al., 
2009).
In GBM, PDK1 is directly and indirectly part of critical 
molecular pathways, which regulate several growth factors and 
oncogenes, including phosphatidylinositol-3-kinase (PI3K)/
PDK1/protein kinase B (Akt) pathway, PI3K–mammalian target 
of rapamycin (mTOR) crosstalk pathway, and phosphatase and 
tensin homolog (PTEN)-Akt-mTOR signaling pathway (Dunn et 
al., 2012; Krakstad and Chekenya, 2010). In addition, cytokines 
such as interleukin-6 have been reported to influence the PI3K/
AKT signaling pathway (Guven-Maiorov et al., 2014). Therefore 
and regarding all said, it is very important to clarify the effects of 
inhibiting this protein & its potential as future therapeutic agent. 
To do so, the induced drug perturbation in glioblastoma cancer 
cells through in vitro assays by performing a multiparametric 
characterization of dose-response of two PDK1 inhibitors (G51 
and FC100) was parameterized.
As there is a need to develop and improve in vitro models 
for drug discovery in GBM (Nesi, 2011), the overall context of 
this perturbation studies is the new-age pharmacology so-called 
quantitative and systems pharmacology (Sephton et al., 2009).
MATERIALS AND METHODS
Reagents and cells
The U-87 MG human glioblastoma astrocytoma cell line 
was kindly made available by the Center for Neuroscience and 
Cell Biology of the University of Coimbra (Portugal).
The PDK1 inhibitors called G51 (C25H25N5O4) and 
FC100 (C13H12N4O3S) were synthesized and provided within a 
collaboration with Prof. Simona Rapposelli from the Department 
of Pharmacy of the University of Pisa (Italy).
High glucose Dulbecco’s modified Eagle’s medium 
(HG-DMEM), dimethyl sulfoxide (DMSO), phosphate-buffered 
saline (PBS), methanol (MeOH), and sulphorhodamine B sodium 
salt (SRB) were purchased from Sigma-Aldrich Chemical S.L. 
(Sintra, Portugal). Heat-inactivated fetal bovine serum (FBS) and 
penicillin-streptomycin were obtained from Invitrogen (Barcelona, 
Spain). Tris(hydroxymethyl)aminomethane was obtained from 
National Diagnostics (Hessle Hull, UK).
Cell culture and drug treatment
Cells were seeded at a 1.5 × 105 cells/ml density and 
were grown at 37 °C under humidified atmosphere, containing 
5% CO2, in HG-DMEM (4.5 g/l glucose) supplemented with 
10% heat-inactivated FBS, 100 U/mol penicillin, and 100 µg/ml 
streptomycin.
The PDK1 inhibitors G51 and FC100 were solubilized 
in pure DMSO as 10 mM solutions, followed by a dilution with 
PBS to obtain 1 mM samples containing 10% DMSO.
For dose-response experiments, cells were plated in 
triplicate at a 5.7 × 104 cells/ml density in 24-well plates, allowed 
to adhere overnight, treated with five different dosages (2.5, 5, 10, 
20, and 40 µM) of each compound, and incubated for time periods 
of 24, 48, and 72 hours.
In order to determine whether the PDK1 inhibitors 
effects were cytostatic or cytotoxic, two sets of U-87 MG cells 
were exposed to the compounds under the same conditions and for 
the same period of time. At the end of a 72 hours exposure, one 
set of cells was assayed while for the other the drug-containing 
medium was replaced by fresh culture medium. The incubation 
continued for an additional 72 hours, after which the plate was 
assayed as to cytostatic or cytotoxic effects through methods 
reported in the literature (Jenkins, 2013).
Measurement of drug response
The SRB assay for evaluation of cell density was used 
(Monks et al., 1991). Cells were fixed by adding 1 ml of cold 
1% acetic acid/MeOH, followed by storage overnight at 4°C. The 
fixed cells were then placed at room temperature for 24 hours; 
500 µl of SRB (0.5% w/v) were added to each well and they were 
incubated at 37°C for 1 hour. The plates were washed with 1% 
acetic acid to remove unbound SRB and allowed to dry overnight. 
SRB was solubilized with 1 ml of 10 mM Tris (pH 10) per well, 
shaken, and the supernatant was transferred to a 96-well plate 
to measure the optical density at 540 nm (on a Bio-Tek µQuant 
MQX200 Spectrophotometer UV-VIS).
Dose-response curve fitting and data calculations
Triplicate dose-response data were fitted to a logistical 
sigmoidal model (Eq. 1, where y is a response measure at dose 
D), using nonlinear least-squares regression (in GraphPad Prism 
Software, Version 5.00 for Windows).
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The different dose-response parameters for each individual 
curve were estimated, including GI50,  total growth inhibition (TGI), 
HS, minimum effect (Einf), and Emax or E0. Based on the type of 
model used to predict these parameters, a HS of −1 was considered 
as standard, a HS lower than −1 is steeper, and a value higher than 
−1 is shallow (Jenkins, 2013). In addition, the parameter area under 
the curve (AUC) was calculated, defined as the sum of measured 
responses (relative viability) at all tested drug concentrations. 
Hence, AUC = 9 corresponds to an inactive compound, whereas 
smaller AUC values represent biologically significant drug activities 
regarding inhibition of cell proliferation and/or cell death promotion. 
The drug concentration resulting in TGI was determined when the 
amount of protein at the end of each drug incubation period was 
found to be unchanged relative to the control.
The values for IC50 and % inhibition direct to PDK1 
(for a 10 µM concentration) were previously obtained for the 
inhibitors under study at Prof. Rapposelli´s laboratory (Invitrogen 
Z’-LYTE® biochemical assay).
Regarding the SRB assay (Fallahi-Sichani et al., 2013), 
three types of measurements were performed: growth control (C0), 
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control of treatment for each chosen time-point (C24h, C48h, 
and C72h), and cell population density upon treatment (T). The 
percentage of SRB retention was computed in GraphPad Prism 
Software (Version 5.00 for Windows), using the one-way analysis 
of variance method followed by multiple comparison Turkey’s 
test. Differences were considered statistically significant for p < 
0.05, p < 0.01, and p < 0.001.
All data were processed under high-quality control: the 
analysis of average, amplitude of the sample, standard deviation 
(SD), coefficient of variation, standard error of the mean (SEM), 
and Dixon’s Q test (90 % of confidence) were calculated. After 
computational model fitting, the goodness of fit was also evaluated 
by the coefficient of determination (R2).
RESULTS AND DISCUSSION
Drug-induced perturbation
The perturbation at the cellular system U-87 MG cells, 
by a range of dosages of two PDK1 inhibitors G51 and FC100 
(Fig. 1A and B, respectively), was evaluated by SRB assay.
For G51, the most significant perturbation was verified 
after 72 hours of incubation for the higher dose—40 µM (Fig. 2A).
Also, the cells display a very significant perturbation at 20 
µM. At 24 and 48 hours, there is no significant meaning of system 
perturbation. Further analysis of the systematic perturbation of 
the tested inhibitors on the cell response (Fig. 3) shows that when 
comparing the lower concentrations at 72 hours to doses in the 
range between 10 and 40 µM at the lower time points of treatment, 
there was a higher effect for the latter. In addition, for 72 hours of 
incubation, there were no significant differences between the 72 
hours control (C72h) and the 2.5, 5, and 10 µM doses tested.
In the case of FC100, the significances marked in Figure 
1B are related with the cells growth as the increase of % SRB 
retention across time-points in the presence of drug at the five 
concentration levels. These are directly correlated with the % SRB 
retention of control growth and as a result, there is no significant 
disruption on the cellular system made by this drug.
Drug perturbation effects evaluation
Analyzing the effects of induced drug perturbation, 
G51 drug appears to have a cytostatic effect as the cells grow and 
undergo mitosis 3 days after removal of the drug (time-point 144 
hours), with an extremely significant mean for the 20 and 40 µM 
doses (Fig. 3).
Regarding the FC100 drug, the perturbation of the 
cellular system U-87 MG fails to produce a specific cytostatic 
or cytotoxic effect, irrespective of the concentration tested. In 
fact, even showing a significant difference between cells treated 
at 72 hours and cells counted 3 days after FC100 removal (time-
point 144 hours), which could indicate a cytostatic effect, there 
is no significant reduction in the percentage of SRB retention of 
these cells, when compared to the control, for any of the time-
points considered in the study (24, 48, and 72 hours) as shown 
in Figure 2B. However, by multiple comparison analysis (Fig. 
4), the higher significant mean difference comparing the time-
points 72 and 144 hours was for the dose 40 µM, whereas, it was 
not too much different from the effect of the other doses (SD 
= 0.07). In addition, there is no evidence of a cytotoxic effect 
induced by perturbation. However, FC100 was found to induce 
a higher cellular perturbations in the first 24 hours of treatment 
when compared to 48 and 72 hours (Fig. 3). It is also interesting 
Figure 1. Molecular structures of G51 (A) and FC100 (B) compounds.
Oliveira et al. / Journal of Applied Pharmaceutical Science 9 (04); 2019: 058-065 061
to note that there are no significant perturbation differences 
between the time-points 48 and 72 hours upon treatment with the 
drug. This might indicate that the almost negligible perturbation 
due to FC100 is induced immediately—shown at 24 hours—on 
this cellular system. Inclusively, during the first 24 hours, the cell 
response to FC100 seems to be similar for all the dosages tested 
(SD = 0.06).
Multiparametric dose-response analysis
In the present study, variation in features other than 
potency was analyzed in two systems levels—molecular and 
cellular (Table 1)—in order to better understand both the response 
induced by these two PDK1 inhibitors and disease. Thus, at 
molecular system level, tests were done directly to PDK1 kinase, 
and the % inhibition and IC50 were evaluated, clarifying the 
potency of the drugs. As a result, FC100 proved to be notoriously 
more potent than G51. On the other hand, at the cellular system 
level, parameters such as GI50, TGI, HS, Einf, Emax, and AUC were 
evaluated to gather the biological importance of variation in other 
parameters than potency.
In general, GI50 values are lower for FC100 compound 
when compared to G51; however, the former seems not to produce 
a high enough perturbation to completely inhibit cell growth (TGI) 
up to 40 µM, indicating that IC50 and GI50 fail to indicate the most 
promising compound.
When analyzing AUC, their smaller values are for G51 
as compared to FC100, reflecting a higher drug activity for the 
first one. In addition, the results obtained for TGI agree with AUC 
Figure 2. Perturbation effect of G51 (A) and FC100 (B) compounds at the cellular system-level of U87-MG cell 
line, n = 3. The bars represent ± SEM. *p < 0.01 versus control, #p < 0.001 versus control, +p < 0.001 versus 
72 hours treatment.
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data, confirming the poor activity of this compound toward this 
cellular system.
Analyzing the HS parameter for G51 drug (Fig. 5; Table 
1), it was found that, generally, the target in this cellular system 
is always fully available during the experimentation and might 
represent a drug with polypharmacology (HS < −1).
On the other hand, for FC100 drug (Fig. 6; Table 1), 
this parameter shows that a subpopulation of cells were simply 
unaffected and that the target of this compound is not always 
available in the U-87 MG cell line during the first 48 hours. 
However, surprisingly, at 72 hours of drug treatment, there is a 
steeper HS, indicating availability of drug target and some activity 
of the compound, also confirmed by its lowest value of AUC.
Regarding the measurement of drug efficacy for 
anticancer drugs, the high maximal effect is obtained when Emax ~ 
Einf ~ 0, which corresponds to 100% of cell death (Fallahi-Sichani 
et al., 2013). Analyzing our data, G51 shows closer values to 0 
when compared to FC100.
In a novel drug discovery and development era, where 
challenges are found in every branch of the process, involving a 
variety of players, from the basic science, clinical, and industry, 
all parts must be integrated in a harmonic manner. Specifically, 
we are talking about of the emergent concept of Academic Drug 
Discovery Centres (Schultz Kirkegaard and Valentin, 2014), 
crowdfunding initiatives (Houghton et al., 2007), back-up 
strategies (Monks et al., 1991), and development of integrative 
analysis (Kell and Goodacre, 2014). Also, the “wet laboratory” 
needs to keep up with all of the updates coming from these areas 
and contribute actively to the improvement of this business. As 
a result, the purpose of this study was to develop a new way of 
rethinking cellular drug response and ultimately contribute for a 
better prediction of drug effects by exploring how the actual focus 
on potency ignores the potential impact of other dose-response 
parameters to analyze the action of two PDK1 inhibitors in GBM 
at the cellular system-level.
As previously reported, PKD1 is directly and indirectly 
involved in a variety of human cancers, specially breast cancer 
(Dragojlovic and Lynd, 2014; Provins et al., 2014; Schultz 
Kirkegaard and Valentin, 2014; Vichai and Kirtikara, 2006), but also 
involved in ovarian, prostate, pancreatic cancers, and glioblastoma 
(Dunn et al., 2012; Fyffe and Falasca, 2013; Hernandez-Aya and 
Gonzalez-Angulo, 2011; Kell and Goodacre, 2014; Raimondi 
and Falasca, 2011). In our experiments, both inhibitors perturbed 
the U-87MG cellular system, supporting the PDK1 aberration 
in GBM reported before (Dunn et al., 2012; Fyffe and Falasca, 
2013). However, different effects were observed—F100 induced 
cell growth at 24 and 48 hours, while G51 led to cell growth 
arrest. An important phenomenon as polypharmacology can be the 
reason for the observed results since G51 and FC100 compound 
show different degrees of potency (Table 1), also it is supported 
by the HS analysis. However, the highly potent compound toward 
PDK1 inhibition (FC100) does not induce a specific anticancer 
effect on the U-87MG cellular system, although having some 
nonspecific activity after 72 hours of treatment, while G51 shows 
a cytostatic effect. This indicate two important things: first, the 
cytostatic effect shown by G51 might not be related exclusively to 
PDK1 inhibition; second, the parameter potency cannot be used to 
exclusively to stratify drugs during the R&D process.
Regarding the first conclusion, it has been shown 
by literature that PDK1 controls migration and malignant 
transformation but not cell growth and proliferation in PTEN-null 
lymphocytes (Dragojlovic and Lynd, 2014). It is also reported that 
in breast cancer, PDK1 just plays an essential role in regulating 
cell migration (Provins et al., 2014), reinforcing our results 
regarding the lack of growth inhibition effect or cell killing on 
this cell line. Therefore, in a therapeutic context, PDK1 inhibitors 
possibly play a role in combination with other antitumor agents 
to treat glioblastoma multiforme. This conclusion is supported 
by the literature already published: PDK1 and checkpoint kinase 
1 (CHK1) inhibition is required to induce antitumor effect in 
Figure 3. Multiple comparison analysis of the G51 induced perturbation in the cellular 
system-level U-87 MG cell line. The bars represent the mean difference of perturbation.
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GBM in vivo by killing glioblastoma stem-like cells (Sargeant 
et al., 2007), as well as, another study states that by reversing 
the Warburg Effect, combined targeting of PDK1 and epidermal 
growth factor receptor inhibited glioblastoma multiforme growth 
and proliferation (Fyffe and Falasca, 2013).
Talking about the parameter potency, it fails to indicate 
our lead compound to treat glioblastoma multiforme. Therefore, 
this suggests that it is not the most important parameter to 
characterize a cellular response, and so, to stratify drugs at early 
stage of the drug discovery process, as it has been done along these 
years. Inclusively, other parameters that did not receive too much 
attention seem to emerge now in our study as better predictors to 
stratify compounds. For example, HS starts to gain more attention 
on the literature (Guven-Maiorov et al., 2014; Jenkins, 2013). 
Also, regarding our results, the shape of dose-response curves 
is affected by polypharmacology and further analysis of G51 
Figure 4. Multiple comparison analysis of the FC100 induced perturbation in the cellular system-level U-87 MG cell line. The bars represent the mean difference of 
perturbation.
Oliveira et al. / Journal of Applied Pharmaceutical Science 9 (04); 2019: 058-065 064
compound throughout a kinase profile and at the proteomics level 
will confirm it.
CONCLUSION
Overall, this study suggests that in this cell 
line, analyzing other parameters seems to not yield extra 
information when it comes to characterize drugs profile 
at the cellular system level as in the end, those parameters 
correlated with each other. However, here both compounds 
tested in U-87MG, HS gathered the same information as the 
% inhibition PDK1 direct performed by Z’LYTE® Assay at 
the University of Pisa, because, as we see, the compound 
that most inhibits PDK1 is the one that does not show effect. 
Therefore, the results from both assays agree when it comes 
to the polypharmacology of such compound. So, HS should 
be further explored as a marker that yields polypharmacology 
since a single procedure at the cellular level could clarify 
both drug profiles and cellular response, saving the molecular 
studies to reveal and confirm the multiple drug targets and so, 
saving time & reducing costs.
Finally, taking in account that over 50% of failures at 
phases II and III clinical trials are attributed to a lack of efficacy, 
which could be a result of a no optimal drug target (Velpula and 
Tsung, 2014), another question must be done: is PDK1 an optimal 
target to glioblastoma multiforme? In our study, PDK1 inhibition 
does not always result in GBM growth inhibition in this cell 
line. Therefore, further system-level studies in other cell lines 
and in other systems, including at protein level, organism level, 
and other molecular genetics studies should be done to clarify 
the relevance of this target and its validity to treat glioblastoma 
multiforme.
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